Insilico Medicine CEO on Business Strategy
Alex Zhavoronkov, Founder and CEO at Insilico Medicine, discusses the company's business strategy and the opportunities with AI drug discovery. He speaks with Haslinda Amin from the sidelines of 'JPMorgan Global China Summit' in Shanghai. (Source: Bloomberg)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Europe Builds AI Infrastructure With NVIDIA to Fuel Region's Next Industrial Transformation
Europe AI Infrastructure France, Italy and the United Kingdom Support Regional Technology and Cloud Providers Domyn, Mistral AI, Nebius and Nscale to Deploy More Than 3,000 Exaflops of NVIDIA Blackwell Systems for Sovereign AI NVIDIA to Build AI Factory in Germany to Accelerate Industrial Manufacturing Applications in Europe European Telcos Fastweb, Orange, Swisscom, Telefónica and Telenor Build AI Infrastructure With NVIDIA, Enabling Enterprises to Adopt and Build Agentic AI Applications European Enterprises, Startups and Public Sector to Harness Regional NVIDIA Infrastructure to Develop and Deploy Agentic and Physical AI NVIDIA Establishes AI Technology Centers Across Continent to Advance Research, Upskill Workforces and Accelerate Scientific Breakthroughs PARIS, June 11, 2025 (GLOBE NEWSWIRE) -- —NVIDIA GTC Paris at VivaTech—NVIDIA today announced it is working with European nations, and technology and industry leaders, to build NVIDIA Blackwell AI infrastructure that will strengthen digital sovereignty, support economic growth and position the continent as a leader in the AI industrial revolution. France, Italy, Spain and the U.K. are among the nations building domestic AI infrastructure with an ecosystem of technology and cloud providers, including Domyn, Mistral AI, Nebius and Nscale, and telecommunications providers, including Orange, Swisscom, Telefónica and Telenor. These deployments will deliver more than 3,000 exaflops of NVIDIA Blackwell compute resources for sovereign AI, enabling European enterprises, startups and public sector organizations to securely develop, train and deploy agentic and physical AI applications. NVIDIA is establishing and expanding AI technology centers in Germany, Sweden, Italy, Spain, the U.K. and Finland. These centers build on NVIDIA's history of collaborating with academic institutions and industry through the NVIDIA AI Technology Center program and NVIDIA Deep Learning Institute to develop the AI workforce and scientific discovery throughout the regions. 'Every industrial revolution begins with infrastructure. AI is the essential infrastructure of our time, just as electricity and the internet once were,' said Jensen Huang, founder and CEO of NVIDIA. 'With bold leadership from Europe's governments and industries, AI will drive transformative innovation and prosperity for generations to come.' 'France is committed to investing in AI to strengthen our economy, benefit our citizens and uphold our values,' said Emmanuel Macron, president of the French Republic. 'By working closely with our nation's leading technology innovators and NVIDIA, we are equipping researchers, entrepreneurs and public institutions with the tools they need to explore new ideas, tackle complex challenges and help shape the future of AI for France.' 'Just as coal and electricity once defined our past, AI is defining our future,' said U.K. Tech Secretary Peter Kyle. 'NVIDIA's expansion of its technology center here in the U.K. will be vital in helping us to deliver on our AI ambitions, and their partnership in building the capabilities that will transform our AI Growth Zones into engines of opportunity. This is our Plan for Change in action, bringing together leading innovators to build the compute infrastructure that will drive growth across every region and secure the U.K.'s place as a global AI leader in the age of AI.' 'This agreement represents a strategic step toward strengthening Italy's technological sovereignty and ensuring that our businesses have secure and competitive access to data management,' said Minister of Enterprise and Made in Italy Adolfo Urso. 'The collaboration with top-tier partners such as NVIDIA and Domyn confirms the government's commitment in supporting high-level alliances to foster innovation and the competitiveness of the national production system.' Building Europe's Foundation for AI Infrastructure and InnovationBuilding AI infrastructure requires strategic investment in advanced systems, land and facilities, sustainable energy access, skilled experts and partnerships. To accelerate the development of these national resources, NVIDIA is working with leaders across France, the U.K., Germany and Italy. In France, Mistral AI is working with NVIDIA to build an end-to-end cloud platform powered by 18,000 NVIDIA Grace Blackwell systems in the first phase, with plans to expand across multiple sites in 2026. This infrastructure will enable organizations across Europe to quickly develop and deploy AI using optimized Mistral AI models and validated AI factory designs, accelerating the adoption of agentic AI applications. In the U.K., NVIDIA is collaborating with NVIDIA Cloud Partners Nebius and Nscale to unlock advanced AI capabilities for enterprises and businesses of all sizes. At London Tech Week, the cloud providers announced the first phase of their AI infrastructure development plans to deploy 14,000 NVIDIA Blackwell GPUs to power new data centers, making scalable, secure AI infrastructure widely accessible across the U.K. In Germany, NVIDIA and its partners are building the world's first industrial AI cloud for European manufacturers. This AI factory will be powered by NVIDIA DGX™ B200 systems and NVIDIA RTX PRO™ Servers featuring 10,000 NVIDIA Blackwell GPUs to enable Europe's industrial leaders to accelerate every manufacturing application, from design, engineering and simulation to factory digital twins and robotics. In Italy, NVIDIA is working with Domyn and the government to advance the nation's sovereign AI capabilities. Domyn is developing its Domyn Large Colosseum reasoning model on its supercomputer, Colosseum, with NVIDIA Grace Blackwell Superchips, in alignment with its mission to support regulated industries in adopting AI. European Telcos Build AI Infrastructure With NVIDIA for Regional EnterprisesNVIDIA is also working with leading European telecommunications providers — including Orange, Fastweb, Swisscom, Telefónica and Telenor — to develop secure, scalable sovereign AI infrastructure across the region. Orange is accelerating the development of enterprise-grade AI, including agentic AI, large language models and personal AI assistants, using Orange Business' Cloud Avenue, built on high-performance NVIDIA infrastructure. Fastweb introduced MIIA — an Italian language model to support generative AI applications — trained and running on its NVIDIA DGX AI supercomputer. Telenor is expanding its sovereign AI infrastructure in Norway with a new, renewable-powered data center, in addition to hosting a partner's multilingual AI translation service, available in over 100 languages. Swisscom is launching new AI services, including GenAI Studio and AI Workhub hosted on its sovereign AI NVIDIA DGX SuperPOD™-based infrastructure, empowering Swiss enterprises to rapidly build and scale AI applications. Telefónica is piloting a distributed edge AI fabric across Spain with hundreds of NVIDIA GPUs to deliver low-latency, privacy-focused AI services. These collaborations enable enterprises to develop and deploy customized AI models and agentic applications at scale, tapping into telcos' extensive networks and trusted role as critical infrastructure providers. NVIDIA AI Technology Centers Fuel Research, Upskilling and Scientific ProgressNVIDIA is establishing and expanding technology centers in Germany, Sweden, Italy, Spain, the U.K. and Finland to accelerate AI skills development, research and infrastructure for the continent's enterprises and startups. The Bavarian AI center in Germany, intended to be established in collaboration with the Bayern KI consortium, will advance research in fields including digital medicine, stable diffusion AI and open-source robotics platforms to foster global collaboration. The Sweden AI center will advance world-class AI research with support from NVIDIA experts and hands-on NVIDIA Deep Learning Institute training to help with upskilling. The Italy AI center will expand to include new AI factory deployments with the CINECA consortium. The Spain AI center will expand to include a new AI factory with the Barcelona Supercomputing Center. The U.K. AI center will accelerate the U.K.'s most groundbreaking research in embodied AI, materials science and Earth systems modeling. The Finland AI center enables researchers to accelerate AI research and applications for computer vision, machine learning and AI for science. These strategic initiatives across Europe build on NVIDIA investments in building AI infrastructure worldwide, including in Taiwan and the Middle East. Watch the NVIDIA GTC Paris keynote from Huang at VivaTech, and explore GTC Paris sessions. About NVIDIANVIDIA (NASDAQ: NVDA) is the world leader in accelerated computing. For further information, contact: Corporate CommunicationsNVIDIA Corporationpress@ Certain statements in this press release including, but not limited to, statements as to: with bold leadership from Europe's governments and industries, AI driving transformative innovation and prosperity for generations to come; technology development in European nations; the benefits, impact, performance, and availability of NVIDIA's products, services, and technologies; expectations with respect to NVIDIA's third party arrangements, including with its collaborators and partners; expectations with respect to technology developments; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections based on management's beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA's reliance on third parties to manufacture, assemble, package and test NVIDIA's products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA's existing product and technologies; market acceptance of NVIDIA's products or NVIDIA's partners' products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA's products or technologies when integrated into systems; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company's website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances. © 2025 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, DGX, NVIDIA DGX SuperPOD and NVIDIA RTX PRO are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice. A photo accompanying this announcement is available at
Yahoo
38 minutes ago
- Yahoo
High Growth Tech Stocks To Watch In June 2025
As of June 2025, global markets have been experiencing notable shifts with U.S. stocks climbing for the second consecutive week, led by small-cap stocks and a strong performance in the information technology sector, driven by positive sentiment around artificial intelligence-related developments. In this environment of cautious optimism and technological advancement, identifying high-growth tech stocks involves looking for companies that are well-positioned to leverage emerging technologies like AI while navigating broader economic challenges such as trade tensions and fluctuating labor market conditions. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Shanghai Huace Navigation Technology 24.44% 23.48% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ Rakovina Therapeutics 40.75% 16.49% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ JNTC 54.24% 87.93% ★★★★★★ Click here to see the full list of 748 stocks from our Global High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Simply Wall St Growth Rating: ★★★★★☆ Overview: ISU Petasys Co., Ltd. is a global manufacturer and seller of printed circuit boards (PCBs) with a market capitalization of ₩3.02 billion. Operations: ISU Petasys focuses on the global production and sale of printed circuit boards (PCBs). The company's operations are supported by a market capitalization of ₩3.02 billion. ISU Petasys has demonstrated a robust growth trajectory, with earnings surging by 91.4% over the past year, significantly outpacing the electronic industry's average of 16%. This performance is underpinned by a strong forecast for both revenue and earnings; expected to grow annually at 16.7% and 30.4%, respectively, surpassing broader market expectations. Despite high volatility in its share price and a considerable level of debt, the company's strategic initiatives like the recent Follow-on Equity Offering of KRW 282.53 billion indicate proactive steps to bolster financial flexibility and fuel further growth. With R&D investments aligning with these ambitious growth targets, ISU Petasys is positioning itself as a dynamic contender in its sector, though challenges such as shareholder dilution need careful monitoring. Delve into the full analysis health report here for a deeper understanding of ISU Petasys. Examine ISU Petasys' past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Ningbo Yunsheng Co., Ltd. focuses on the research, development, manufacture, and sale of rare earth permanent magnet materials in China, with a market cap of CN¥9.41 billion. Operations: The company generates revenue primarily from the Neodymium Iron Boron segment, which amounts to CN¥5.14 billion. Ningbo Yunsheng has shown a remarkable turnaround, transitioning from a net loss to reporting a net income of CN¥95.08 million for the full year ended December 31, 2024. This improvement is reflected in its annual revenue growth of 17.8% and an impressive earnings growth forecast at 39.8% per year, outpacing the Chinese market's average. The company's strategic focus on R&D is evident with significant investments aimed at fostering innovation and maintaining competitive edge in the tech sector, aligning with industry shifts towards advanced manufacturing technologies. Recent activities like their comprehensive share buyback program further underscore their commitment to enhancing shareholder value amidst these positive financial dynamics. Click here and access our complete health analysis report to understand the dynamics of Ningbo Yunsheng. Gain insights into Ningbo Yunsheng's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Beijing Zhong Ke San Huan High-Tech Co., Ltd. operates in the high-tech industry with a market capitalization of approximately CN¥14.07 billion. Operations: Zhong Ke San Huan High-Tech primarily engages in the production and sale of high-performance magnetic materials. The company focuses on leveraging advanced technology to cater to various industries, enhancing its competitive position in the market. Beijing Zhong Ke San Huan High-Tech has demonstrated resilience with a significant turnaround from a net loss to a net income of CNY 13.49 million in Q1 2025, contrasting sharply with the previous year's loss. This recovery is part of a broader trend where the company's annual revenue growth is projected at 19.9%, outstripping the Chinese market average of 12.4%. Moreover, its earnings are expected to surge by an impressive 43.9% annually, eclipsing sector norms significantly. Despite recent challenges indicated by reduced dividends and fluctuating sales figures, such strategic financial maneuvers and robust R&D investments underscore its potential for sustained growth in the competitive tech landscape. Navigate through the intricacies of Beijing Zhong Ke San Huan High-Tech with our comprehensive health report here. Evaluate Beijing Zhong Ke San Huan High-Tech's historical performance by accessing our past performance report. Access the full spectrum of 748 Global High Growth Tech and AI Stocks by clicking on this link. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A007660 SHSE:600366 and SZSE:000970. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Medscape
38 minutes ago
- Medscape
Can a TKI Boost Anti-PD-L1 Activity in NSCLC?
Can adding a TKI that targets programmed death ligand 1 (PD-L1) to a monoclonal antibody that also targets PD-L1 improve outcomes over the monoclonal antibody alone in locally advanced, unresectable non-small cell lung cancer (NSCLC)? Researchers in China have come in with a qualified yes. The authors of the new study found that a combination of anlotinib, an oral small-molecule TKI, and benmelstobart (TQB2450), a humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody that targets PD-L1, improved progression-free survival (PFS) compared with benmelstobart alone after concurrent/sequential chemoradiotherapy (60 Gray ± 10%). A downside of taking the TKI was a significant increase in side effects, Ming Chen, MD, PhD, lead investigator of the R-ALPS trial, reported at American Society of Clinical Oncology (ASCO) 2025. Study Results 'Our key finding demonstrated significant improvement in median PFS with the combination of benmelstobart plus anlotinib, with a median PFS of 15.1 months compared to 9.7 months with benmelstobart alone and 4.2 months with placebo,' said Chen, while presenting the abstract at the meeting. PFS was the primary endpoint of the study. Ming Chen, MD, PhD 'This translated into a reduced risk of disease progression with a hazard ratio of 0.49 for the combination arm and 0.53 for benmelstobart alone,' vs placebo, said Chen, who is director of Radiation Oncology at the Sun Yat-sen University Cancer Center in Guangzhou, China. The P values for both were less than .0001. Chen reported results of an interim analysis of the phase 3 R-ALPS study, which randomized 553 patients to one of three treatment groups after all received concurrent/sequential chemoradiotherapy: Benmelstobart alone, benmelstobart plus anlotinib, or placebo. Twelve-month PFS rates were 54.9% in the combination group, 45.7% in the benmelstobart alone group, and 26.4% in the placebo group. The data analysis of overall survival rates has not been completed, Chen said. Among secondary endpoints, overall response rates were 25.6% ( P = .01), 23.3 ( P = .0318), and 12.9% for the combination, benmelstobart alone, and placebo groups, respectively. The disease control rates were 84.5% ( P = .0067) and 86.1% ( P = .0023) for the combination and benmelstobart alone groups, respectively, and was 70.5% for the placebo group. Safety Profile 'Manageable' or 'Significant'? The combination group had consistently higher rates of adverse events than the other two groups. Chen said the safety profile of adding anlotinib to benmelstobart was 'manageable,' while Shankar Siva, PhD, MBBS, a discussant at the oral abstracts session, characterized the toxicity profile of the study as 'significant.' Shankar Siva, PhD, MBBS Overall, the rates of grade 3-5 treatment-related adverse events (TRAEs) were 50% in the combination group, 32% in the benmelstobart alone group, and 21% in the placebo group. The rates of serious TRAEs were 38.3%, 33% and 26.5%, respectively. Hematologic toxicities were not significantly different across the three groups, Chen said, but the following four biochemical measures were significantly elevated in the combination group: Antistreptokinase, creatine phosphokinase, thyroid-stimulating hormone, and amylase. Among the grade 3-5 non-hematologic TRAEs, rates of infectious pneumonia, hypertension, and hemoptysis were significantly higher in the combination group: 8.1%, 8.6%, and 2.4%, respectively, vs 4.7%, 0.9%, and 0.5% in the benmelstobart alone group and 5.3%, 1.8%, and 0.8% in the placebo group. Chen added that the rates of radiation pneumonitis and immune pneumonitis 'were very mild in all three arms,' with rates below 3%. Elaborating on his different take on the combination treatment's safety profile from Chen's, Siva said the incidence of high-grade adverse events in this study was notable. 'More targeted or bispecific TKIs' might be worth exploring in a combination treatment after chemoradiotherapy for NSCLC to improve the safety profile, he said, during the session. Knowing biomarkers of benefit and potential toxicity would also be important for using multitarget TKIs in combination therapies after chemoradiotherapy for NSCLS, noted Siva, who is a radiation oncologist at Peter MacCallum Cancer Centre in Melbourne, Australia. One of the limitations of the study was that all patients were Chinese, Chen said. Anlotinib was approved for advanced NSCLC in China in 2019. Chia Tai TianQing Pharmaceutical Group funded the study. Chen reported having no relevant financial relationships. Siva reported having financial relationships with AstraZeneca, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, and Varian Medical Systems.
